Neoadjuvant chemotherapy does not increase peri-operative morbidity following radical cystectomy.
Amandeep AroraAhmed S ZugailFelipe PugliesiXavier CathelineauPetr MacekYann BarbéR Jeffrey KarnesMohamed AhmedEttore Di TrapaniFrancesco SoriaMario Alvarez-MaestroFrancesco MontorsiAlberto BrigantiAndrea NecchiBenjamin PradereDavid D'AndreaWojciech KrajewskiMathieu RoumiguiéAnne Sophie BajeotRodolfo HurleRoberto ContieriRoberto CarandoJeremy Yuen-Chun TeohMorgan RoupretDaniel BenamranGuillaume PloussardM Carmen MirRafael Sanchez-SalasMarco MoschiniPublished in: World journal of urology (2022)
This large multicentre analysis with a substantial rate of NAC utilization showed that NAC use does not lead to an increased risk of post-operative complications following RC for BCa. This calls for increasing NAC use to allow patients to avail of its proven oncologic benefit.
Keyphrases
- neoadjuvant chemotherapy
- transcription factor
- end stage renal disease
- locally advanced
- ejection fraction
- newly diagnosed
- lymph node
- chronic kidney disease
- sentinel lymph node
- clinical trial
- prognostic factors
- rectal cancer
- study protocol
- squamous cell carcinoma
- randomized controlled trial
- patient reported outcomes
- risk factors
- cross sectional
- radiation therapy
- early stage
- data analysis